13F Pro

SEC Form 4 reporting owner

Seidenberg Beth C

Seidenberg Beth C has filed 12 Form 4 transactions reported between December 18, 2025 and August 10, 2026, as a reporting owner of Latigo Biotherapeutics, Inc., Director of Sagimet Biosciences Inc., Director of Kyverna Therapeutics, Inc. and a reporting owner of Vera Therapeutics, Inc..

Name as filed: SEIDENBERG BETH C

Open-market buys, 24 mo
$1000K
1 lines
Open-market sales, 24 mo
None
reported
Companies
4
with Form 4 filings
Latest transaction
Aug 10, 2026
transaction date

Roles and reported holdings

  • LTGOLatigo Biotherapeutics, Inc.
    Aug 10, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • SGMTSagimet Biosciences Inc.
    Jun 12, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • KYTXKyverna Therapeutics, Inc.
    Dec 18, 2025 – May 27, 2026

    Director

    Held indirectly (latest line)869,317 sh as of Dec 18, 2025 · Form 4

    24 months: $1000K bought

  • VERAVera Therapeutics, Inc.
    May 21, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

Transaction history

All 12 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Aug 10, 2026LTGOConversion of derivativeCode C · indirect2,066,857—Form 4
Aug 10, 2026LTGOConversion of derivativeCode C · indirect165,519—Form 4
Aug 10, 2026LTGOConversion of derivativeCode C · indirect1,484,401—Form 4
Aug 10, 2026LTGOConversion of derivativeCode C · indirect3,464,072—Form 4
Aug 10, 2026LTGOConversion of derivativeCode C · indirect1,027,635—Form 4
Aug 10, 2026LTGOConversion of derivativeCode C · indirect3,547,842—Form 4
Aug 10, 2026LTGOConversion of derivativeCode C · indirect938,979—Form 4
Jun 12, 2026SGMTDirectorGrant or awardCode A · direct39,567—Form 4
May 27, 2026KYTXGrant or awardCode A · direct20,582—Form 4
May 27, 2026KYTXGrant or awardCode A · direct5,093—Form 4
May 21, 2026VERAGrant or awardCode A · direct17,084—Form 4
Dec 18, 2025KYTXDirectorOpen-market purchaseCode P · indirectAlso reported by Westlake BioPartners Opportunity Fund I, L.P.133,333$1000K@ $7.50Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.